This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Aloe Polymannose Improves Function in AD Patients

HOUSTON, Tex.—A new study by University of Miami researchers found an Aloe polymannose multinutrient complex (APMC) improved cognitive and immune function of Alzheimer's disease patients. The study, "The Effect of an Aloe Polymannose Multinutrient Complex on Cognitive and Immune Functioning in Alzheimer’s Disease," was published in the Journal of Alzheimer’s Disease in January 2013 (J Alzheimers Dis. 2013;33(2):393-406.).

In the trial, participants consumed four teaspoons of APMC daily for 12 months. Researchers tested cognitive function using ADAS-cog cognition score and stem cell production at baseline, three, six, nine and 12 months. By nine months, the average ADAS-cog cognition score improved drastically, with 46 percent of sample showing "statistically-significant improvement" from baseline to 12 months. The APMC patients also averaged a 377-percent increase in stem cell production, measured by CD14+ cells in the blood.

Researchers noted the mechanism of interaction between APMC and cognitive function is unclear, and they recommended further study on the correlation. Lorand Labs, maker of the BiAloe® APMC used in the trial, agreed, noting the long-term benefits require more investigation.

“We do not want our industry audiences or the public to think that Lorand Labs

believes that BiAloe® is in any way a treatment, cure or prevention of any disease. We

know and believe that the results of this pilot study are very interesting and show

promise; however, we are looking forward to more independent research to determine

if any long‐term benefit can be derived from the daily use of a BiAloe® multinutrient

complex," said Santiago Rodriguez, Ph.D., CEO of Lorand Labs.

comments powered by Disqus